EGFR and KRAS mutations in the non-tumoral lung. Prognosis in patients with adenocarcinoma

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Chalela Rengifo, Roberto José, 1985-
• dc.contributor.author Bellosillo Paricio, Beatriz
• dc.contributor.author Curull Serrano, Víctor
• dc.contributor.author Longarón Rozalen, Raquel
• dc.contributor.author Pascual Guàrdia, Sergi, 1979-
• dc.contributor.author Badenes Bonet, Diana, 1987-
• dc.contributor.author Arriola Aperribay, Edurne
• dc.contributor.author Sánchez-Font, Albert
• dc.contributor.author Pijuan Andujar, Lara
• dc.contributor.author Gea Guiral, Joaquim
• dc.date.accessioned 2020-02-10T08:22:19Z
• dc.date.available 2020-02-10T08:22:19Z
• dc.date.issued 2019
• dc.description.abstract Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutations observed in ADC can also be observed in the non-neoplastic lung tissue, as well as the short-term prognosis implications of this finding. Methods: Non-tumoral lung parenchyma specimens obtained during surgery from 47 patients with EGFR and/or KRAS abnormalities in their ADC tumors underwent similar genomic testing. Short-term outcomes were also recorded. Results: The same mutations were present in the tumor and the histologically normal tissue in 21.3% of patients (SM group). Although local recurrences were similar in both groups, distant metastases were more frequent in the former (60 vs. 5.4%, p < 0.001). Moreover, SM patients showed lower time-to-progression (8.5 vs. 11.7 months, p < 0.001) and disease-free survival (8.5 vs. 11.2 months, p < 0.001). COX regression showed a higher risk of progression or death (DFS) in the SM group (HR 5.94, p < 0.01]. Similar results were observed when adjusting for potential confounding variables. Conclusions: These results confirm that genetic changes are present in the apparently normal lung in many ADC patients, and this finding has prognostic implications.
• dc.format.mimetype application/pdf
• dc.identifier.citation Chalela R, Bellosillo B, Curull V, Longarón R, Pascual-Guardia S, Badenes-Bonet D et al. EGFR and KRAS mutations in the non-tumoral lung. Prognosis in patients with adenocarcinoma. J Clin Med. 2019 Apr 17;8(4):529. DOI: 10.3390/jcm8040529
• dc.identifier.doi http://dx.doi.org/10.3390/jcm8040529
• dc.identifier.issn 2077-0383
• dc.identifier.uri http://hdl.handle.net/10230/43531
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Journal of Clinical Medicine. 2019 Apr 17;8(4):529
• dc.rights Copyright © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Adenocarcinoma
• dc.subject.keyword EGFR
• dc.subject.keyword KRAS
• dc.subject.keyword Mutations
• dc.subject.keyword Prognosis
• dc.title EGFR and KRAS mutations in the non-tumoral lung. Prognosis in patients with adenocarcinoma
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion